Félix Couture

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 543 citations · Full text

Cobimetinib Versus Regorafenib, Oncology, Medicine +10

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer

Eric X. Chen, Derek J. Jonker, Jonathan M. Loree et al. · JAMA Oncology · 2020 · 377 citations · Full text

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

Irwin Walker, Tony Panzarella, Stephen Couban et al. · The Lancet Oncology · 2015 · 354 citations

Unrelated Donors, Anti-thymocyte Globulin, Transplantation +9

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher et al. · Nature Medicine · 2019 · 319 citations

Medicine, Melanoma, Immune Checkpoint Inhibitor +4

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text